Drug Trial Radar · NCT07627620
Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer
Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Sep 30, 2027
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- Hunan Cancer HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.
Conditions
- Cervical Cancer
Interventions
CamrelizumabDrug
Intravenous (IV) on Day 1 of each cycle
Famitinib MalateDrug
Famitinib po qd
ChemotherapyDrug
Paclitaxel + cisplatin or carboplatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.